Stolper Co Sells 156 Shares of DaVita Inc. (NYSE:DVA)

Stolper Co cut its stake in DaVita Inc. (NYSE:DVA) by 0.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,856 shares of the company’s stock after selling 156 shares during the quarter. DaVita comprises about 2.3% of Stolper Co’s holdings, making the stock its 14th biggest holding. Stolper Co’s holdings in DaVita were worth $7,025,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Wedmont Private Capital raised its holdings in DaVita by 4.4% in the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock worth $280,000 after purchasing an additional 75 shares in the last quarter. Blue Trust Inc. raised its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares in the last quarter. First Trust Direct Indexing L.P. raised its holdings in DaVita by 3.9% in the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares in the last quarter. Quent Capital LLC raised its holdings in DaVita by 21.0% in the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after purchasing an additional 101 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of DaVita by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after acquiring an additional 104 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at $141,219,407.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares in the company, valued at $141,219,407.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the transaction, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 in the last 90 days. 2.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DVA shares. TD Cowen increased their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Bank of America increased their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Truist Financial increased their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $159.00.

DaVita Stock Performance

Shares of DVA stock opened at $161.05 on Friday. DaVita Inc. has a one year low of $71.84 and a one year high of $166.04. The company’s 50-day moving average is $153.76 and its 200 day moving average is $143.49. The company has a market capitalization of $13.51 billion, a price-to-earnings ratio of 16.98, a price-to-earnings-growth ratio of 0.91 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the prior year, the firm posted $2.08 EPS. DaVita’s revenue for the quarter was up 6.2% on a year-over-year basis. Sell-side analysts expect that DaVita Inc. will post 9.99 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.